Staff in generic medicine jobs at Teva have seen the company achieve a record sales performance in the last 12 months.
The Israel-based generics and consumer health specialist generated annual net sales of $16.1 billion (£9.99 billion) during 2010, up by 16 per cent compared to the year before.
A key driver of this growth was the demand seen for its market-leading multiple sclerosis treatment Copaxone, with global in-market sales rising by 17 per cent to $3.3 billion.
The year saw Teva complete a number of key acquisitions, including the purchase of the Merck Serono's European women's health business unit Theramex.
More significantly, it also finalised a merger with the German healthcare firm ratiopharm in August 2010, becoming the largest generics company in Europe in the process.
Shlomo Yanai, Teva's president and chief executive officer, said: "2010 was a great year for Teva, a year in which we delivered record-breaking results across all our geographies while strengthening and expanding our global leadership."